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Introduction
　OK-432, which is a penicillin-killed and lyophilized 
preparation of a low-virulence strain（Su）of Streptococ-
cus pyogenes（group A）that was developed by Okamoto 
et al. in 19671, is being successfully used as an 
immunotherapeutic agent in many types of malignan-
cies, including oral cancer2，3.  We have also reported 
that OK-432-based immunotherapy exhibits a marked 
therapeutic effect in patients with oral squamous cell 
carcinoma4，5.  It has been reported that OK-432 elicits 
anti-tumor effects by stimulating immunocompetent 
cells such as macrophages, T cells, and natural killer
（NK）cells, and by inducing multiple cytokines, 
especially interferon（IFN）- γ 6，7.  Further studies have 
suggested that OK-432 induces interleukin（IL）-12 and 
polarizes the T-cell response to a helper T-cell 1（Th1）
dominant state in mice8, and that local injection of OK-
432 augments the Th1-type T-cell response of tumor-
draining lymph node cells9.  We have previously 
reported that OK-432 induced IFN- γ as well as 
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augmentation of the NK cell activity in 16 of 18 oral 
cancer patients（88.9％） 10.  Most recently, both we and 
other investigators demonstrated that OK-432 induces 
the maturation of dendritic cells（DCs） , which are 
professional antigen-presenting cells, and that OK-432-
stimulated DCs can induce tumor antigen-specific 
cytotoxic T-lymphocytes（CTLs） 11―14.  It has been 
elucidated that OK-432, which is generally called a 
“non-specific immunotherapeutic agent” or “old BRM”, 
induces tumor-antigen specific immunity, and therefore 
OK-432 is being watched with great interest.  While 
previous studies have helped to clarify the cellular 
mechanism of the OK-432-induced anti-cancer immu-
nity which was described above, there has been limited 
progress in elucidating the molecular mechanism, i.e., 
the identification of effective molecule （s）for inducing 
anti-cancer immunity in the whole bacterial prepara-
tion OK-432 and their molecular target （s） , such as 
receptors and signal transducers in immunocompetent 
cells. We recently succeeded in isolating an active 
component, which we designated OK-PSA, and which is 
most responsible for the anti-cancer effect of OK-43215. 
In addition, we clarified, at least in part, the molecular 
mechanism of its enhancing effect on anti-cancer 
immunity.
　Toll-like receptors（TLRs） , which are expressed 
mainly on macrophages and DCs, are recently 
identified receptor molecules that recognize many types 
of pathogens.  Macrophages and DCs are not only 
primarily involved in innate immunity, but are also 
essential for the establishment of adaptive immunity as 
antigen-presenting cells（APCs） .  Thus, TLR signaling 
promotes activation of an innate immune response, and 
then triggers antigen-specific adaptive immunity16，17. 
In immunotherapy against malignant diseases, it has 
been suggested that the induction of tumor antigen-
specific CTLs is crucial for eliminating tumor cells, and 
most immuno-oncologists have discussed how to induce 
adaptive immunity against cancer.  However, the 
precedent activation of the innate immune system is 
essential for the subsequent induction of antigen-
specific immunity.  The TLR-mediated activation of 
innate immunity should be important for establishing 
an effective anti-cancer immune response.  Recently, 
several investigators have proposed the significance of 
the TLR signaling in the induction of anti-cancer 
immunity18,19. We have also reported that TLR4 
signaling is intimately involved in the anti-cancer 
immune response induced by OK-432, as well as by OK-
PSA5，20.
　In this review, we discuss the progress we have made 
to date in our studies, which are focused on the 
establishment of the most effective immunotherapy for 
oral cancer based on OK-432/OK-PSA and TLR4 
signaling.
1. OK-PSA, an active component of OK432
　In an attempt to clarify the molecular mechanism of 
OK-432-induced anti-cancer immunity as well as to 
prepare the more effective immuno-adjuvant for cancer 
therapy, we isolated an active component of OK-432, 
and designated it OK-PSA.
1）Isolation of OK-PSA
　Our strategy to isolate the component that induces 
anti-cancer immunity in OK-432 was to use monoclonal 
antibody（mAb） , which recognizes the IFN- γ -inducing 
molecule, as described in Fig. 1A.  We generated an IgM 
mouse mAb TS-2 that neutralizes IFN- γ as well as the 
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Fig. 1　（A）Our strategy in attempt to isolate the 
effective component to induce anti-cancer im- 
munity from OK-432 using monoclonal antibody 
that recognizes IFN- γ -inducing molecule.（B）
Chemical structure of LTA-1 and LTA-2 proposed 
by Fischer（reference 21） .
killer cell-inducing activities of OK-43215.  OK-PSA was 
isolated as an active component of OK-432 by affinity 
chromatography of a butanol extract of OK-432 on 
CNBr-activated Sepharose 4B bound TS-2 mAb.  OK-
PSA is a glycolipid that has a certain chemical 
structure included in lipoteichoic acids（LTAs）in 
common.  LTAs are membrane-associated amphiphilic 
macromolecules present in Gram-positive bacteria, 
and usually consist of a poly（1,3）glycerophosphate 
backbone covalently linked to a glycolipid or phosphati-
dyl glycolipid.  LTA-1 and LTA-2 contain 2 and 4 acyl 
lipid anchors, respectively21（Fig. 1B） , and it has been 
reported that LTA-2 but not LTA-1 is a potent inducer of 
tumor necrosis factor（TNF）and IFN22. In addition, 
other molecules of the LTA family have also been 
reported23.  However, OK-PSA is not always consistent 
with several known molecules in the LTA family in 
terms of some of its biological activities and in its 
chemical and physical characteristics. Our preliminary 
data demonstrated that OK-PSA contains poly（1,3）
glycerophosphate, a major structure of LTAs, along with 
glycerol and only 2 types of sugar, glucose and mannose. 
 It is possible that OK-PSA is a novel structure in LTA 
family. A determination of the chemical structure of OK-
PSA is now in progress in our laboratories.
2）Effect of OK-PSA on augmentation of anti-
tumor immunity
　Accumulating evidence suggests that the Th1-type 
cytokines such as IFN- γ , TNF- α , TNF- β , IL-2, IL-12 
and IL-18 are greatly involved in killer cell-induction 
and in eliminating cancer cells, while the Th2 cytokines 
inhibit the Th1-mediated anti-cancer effect24，25.  It has 
also been reported that the cytokine balance shifts to 
Th2-dominant in patients with malignant diseases, and 
that this shift leads to inhibition of anti-tumor 
immunity as well as tumor cachexia25，26.  Thus, it is 
important in anti-cancer immunotherapy to selectively 
induce Th1 type-cytokines, and to shift the cytokine 
balance to Th1-dominant in cancer patients.
　Our in vitro experiments revealed that OK-PSA is a 
more potent inducer of Th1-type cytokines and killer 
cell activities on human peripheral blood mononuclear 
cells（PBMCs）than the original OK-43227―30.  We next 
tested the in vivo anti-cancer effect of OK-PSA 
in syngeneic Meth-A tumor-bearing BALB/c mice31. 
The intraperitoneal injection of OK-PSA significantly 
extended the survival time of Meth-A-bearing mice in a 
dose-dependent manner（Fig. 2A） . OK-PSA administra-
tion resulted in a marked induction of Th1-type 
cytokines but not of Th2 cytokines（Fig. 2B） , and killer 
cell activity against antigen-specific target Meth-A but 
not against nonspecific target YAC-1（Fig. 2C） . The 
accelerated cytotoxic activity against Meth-A was 
neutralized by anti-MHC class I Ab as well as by anti-
CD8 Ab（data not shown） .  It was clearly indicated that 
the major effector cells in the OK-PSA-induced cytotoxic 
activity were MHC class I-restricted CD8 ＋ CTLs.  In 
addition, OK-PSA elicited a significant anti-tumor 
effect in athymic nude mice bearing human salivary 
gland cancer, but the effect was relatively weaker than 
that in syngeneic tumor-bearing normal BALB/c mice32. 
This indicates that NK cells also play, at least in part, a 
significant role in OK-PSA-induced anti-cancer immu-
nity, because T-cell function is lost in nude mice.  In 
addition, we recently demonstrated that OK-PSA 
matures DCs, professional APCs, and that OK-PSA-
stimulated DCs induce antigen-specific CTLs in vitro11.
2. TLRs
1）TLRs and their ligands
　The toll gene controls dorsoventral pattern formation 
during the early embryonic development of Drosophila 
melanogaster33.  Interestingly, toll participates in the 
anti-microbial immune responses upon infection in 
adult Drosophila34.  Recently, several mammalian 
homologues of the Drosophila Toll receptor protein
（TLRs）were identified.  TLRs are transmembrane 
proteins and represent a newly recognized family of 
vertebrate pattern recognition receptors in the innate 
immune system.  A prerequisite for the development of 
an effective host defense is the recognition of pathogens. 
TLRs are involved in this first step16，17.  Of the 10 TLRs 
described to date（TLR1 to TLR10） , the ligands for 9 of 
the receptors have been identified.  The major 
exogenous ligands recognized by individual TLRs are 
summarized in Table 117，35，36.
2）Downstream signaling of TLRs
　Downstream signaling of TLRs is summarized in 
Fig. 3. Subsequent to pathogen-associated molecular 
pattern engagement, TLRs initiate the signaling 
via sequential recruitment of myeloid differentiation 
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Table 1　TLRs and their ligands（cited from references 17, 35, 36）
originligandsTLRs
Bacteria
Mycoplasma
Gram （＋） , Mycobacterium,
Mycobacterium
Gram （＋）
Yeast
Virus
Gram （－）
Gram （＋）
Plant
Bacteria with flagella
（Synthetic compound）
（Synthetic compound）
Bacteria
triacyl lipopeptides
diacyl lipopeptides
peptidoglycan
lipoarabinomannan
lipoteichoic acid
zymosan
double-stranded RNA
lipopolysaccharide
lipoteichoic acid
paclitaxel
flagellin
imidazoquinoline
imidazoquinoline
unmethylated
CpG-DNA
?
TLR1/TLR2
TLR2/TLR6
TLR2/   ?
TLR3
TLR4/MD-2
TLR5
TLR7
TLR8
TLR9
TLR10
Fig. 2　Augmentation of anti-cancer immunity by OK-PSA.（A）Prolongation of the survival 
time of tumor-bearing mice by OK-PSA. BALB/c mice which were inoculated i.p. 
syngeneic Meth-A cells, were treated with i.p. administration of 100μ g OK-PSA every 
other day from day 1 through day 9 after the inoculation of Meth-A. ＊ , p ＜ 0.01 ; #, p ＜
 0.05 as compared with control group given saline, analyzed by Kaplan-Meier methods. 
n ＝ 8.（B）Cytokines in the sera derived from Meth-A tumor-bearing BALB/c mice 
administered 100 μ g of OK-PSA i.p. Bars denote SD of triplicate samples. ＊ , p ＜ 0.01 
as compared with respective controls treated with saline.（C）Cytotoxic activities 
against YAC-1, a nonspecific target, and against Meth-A, an antigen-specific target, of 
the OK-PSA（1μ g/ml）-treated spleen cells derived from Meth-A-bearing BALB/c mice. 
Bars denote SD of triplicate samples. ＊ , p ＜ 0.01 as compared with respective controls 
treated with saline.
protein（MyD）88, IL-1R-associated kinase（IRAK） , and 
TNFR-associated factor（TRAF）6, which in turn 
activate downstream mediators such as the nuclear 
factor（NF）- κ B and mitogen-activated protein kinases
（MAPKs） .  It was reported that a newly identified 
molecule, Toll-interleukin 1 receptor（TIR）domain-
containing adapter protein（TIRAP） , acts as an adapter 
in the MyD88-dependent signaling pathways initiated 
via TLR2 and TLR4.  In addition, experiments using 
MyD88-deficient（MyD88 －/－）mice revealed that TLR4 
mediates the signaling in a MyD88-independent fashion 
in addition to a MyD88-dependent fashion. Kawai et al. 
reported that a transcription factor, interferon（IFN）-
regulatory factor（IRF）3, translocated into the nucleus 
in response to LPS in MyD88 －/－ mice. It was suggested 
that the IRF3 activation contributes to the MyD88-
independent pathway.  Recent reports suggested that 
TIR domain-containing adapter induding IFNs（TRIF） , 
a novel adapter molecule, is involved in the MyD88-
independent signaling pathway mediated by TLR3 and 
TLR435，37. 
3）TLRs in cancer therapy
　The activation of TLR signaling triggers the innate 
and adaptive immune response, and frequently induces 
the Th1-type T-cell response.  Therefore, it is possible 
that the ligands of TLRs are able to be effective 
immunoadjuvants for cancer therapy. In this section, 
we review the recent progress made by several 
investigators who have been focusing on the effect of 
TLR ligands in cancer.
3-1）Bacillus Calmette-Guerin cell wall skeleton
（BCG-CWS） : a ligand of both TLR2 and TLR4
　Heat-killed mycobacterial cells suspended in mineral 
oil are potent immunoadjuvants to induce both cell-
mediated and humoral immunity, and the CWS fraction 
of the BCG is the active immunoadjuvant compo-
nent18，38.  It was reported that BCG-CWS enhances the 
cytotoxic activity of T cells and macrophages against 
cancer cells, and elicits an anti-tumor effect in mice and 
rats bearing transplantable and autochthonous tumors. 
In addition, clinical trials with BCG-CWS were 
performed in patients with several types of malignan-
cies, and it was demonstrated that BCG-CWS was 
effective in prolonging the survival of patients, 
especially those with gastric cancer or lung cancer39―41.
　Seya and his co-investigators have reported findings 
which strongly suggest that BCG-CWS augments the 
anti-cancer host response through TLR2 and TLR4. 
They demonstrated that BCG-CWS induces TNF- α
secretion from DCs via both TLR2 and TLR4, and that 
5May, 2004 TLRs in Cancer Immunotherapy
Fig. 3　Schema of the TLR signaling pathway（cited from references 35, 37）
the secreted TNF- α induces the maturation of DCs42. 
The distribution profile of TLR2 and TLR4 matches the 
response profile of cells for BCG-CWS, and further 
investigation by the Seya group showed that the 
peptidoglycan portion of BCG-CWS is an active center 
for cytokine induction and DC maturation via Toll 
signaling38.  These findings strongly suggest that 
signaling via TLRs is closely involved in BCG-CWS-
induced anti-tumor immunity.
3-2）Unmethylated CpG-DNA : a ligand of TLR9
　The specific immunostimulatory effect of bacterial 
genomic DNA was first reported by Tokunaga et al., 
who demonstrated that bacterial DNA activates NK 
cells and induces IFN production in addition to tumor 
regression in some mouse models, but vertebrate DNA 
does not43.  In 1995, Krieg et al. demonstrated that CpG 
motifs in bacterial DNA trigger direct B-cell activa-
tion44.  They also reported that CpG content and 
methylation distinguish vertebrate and bacterial DNAs. 
Genomic DNA from vertebrates, but not from bacteria, 
contains very few CpG dinucleotide motifs.  Further-
more, CpGs are commonly methylated in vertebrates, 
while CpGs are not methylated in bacteria and viruses. 
This suggests the possibility that the immune system 
may have evolved a defense mechanism based on the 
recognition of unmethylated CpG-DNAs, which could be 
a sign of foreign DNA45. 
　The immune response of synthesized oligodeoxynu-
cleotides（ODN）with CpG motifs was examined. Many 
studies demonstrated that unmethylated CpG-ODN 
strongly activates immunocompetent cells such as DCs, 
macrophages, NK cells, T cells, and B cells, and induces 
the Th1-like T-cell response including IFN- γ production 
and CTL induction, both in in vitro and in vivo models45. 
The potential of the CpG-DNA as an adjuvant for 
cancer vaccines was also examined.  The CpG-DNA-
induced activation of DCs creates a Th1-like cytokine 
and chemokine environment in the secondary lymphoid 
organs that promotes cross-priming with strong IFN- γ -
secreting CTLs to the antigens derived from tumors, 
and elicits marked anti-tumor activity46.  Despite its 
promising clinical use, the molecular mechanism by 
which CpG-DNA activates immune cells has remained 
unclear.
　In 2000, the Akira group discovered the receptor 
molecule recognizing bacterial DNA19.  The identified 
protein, TLR9, recognizes the unmethylated CpG motif 
in bacterial DNA, and mediates an innate immune 
response. The researchers generated TLR9 －/－ mice and 
examined the immune effect of CpG-ODN using those 
mice.  TLR9 －/－ mice did not show any response to 
CpG-DNA, including the proliferation of splenocytes, 
inflammatory cytokine production from macrophages, 
and maturation of DCs. TLR9 －/－ mice showed resis- 
tance to the lethal effect of CpG DNA without any 
elevation of serum pro-inflammatory cytokine levels. 
The in vivo CpG-DNA-mediated Th1 response was also 
abolished in TLR9 －/－ mice.  Thus, it was clarified that 
signaling via TLR9 plays an important role in the CpG-
DNA-induced host response.  Clinical trials of CpG-
DNA as an immunotherapeutic agent for cancers and as 
an anti-allergic agent are currently taking place47.
3. TLR4 signaling in OK-432/OK-PSA-induced anti-
cancer immunity
　We hypothesized that signaling via TLRs may be 
involved in the anti-cancer immunity induced by 
OK-432 or OK-PSA, because OK-432 and OK-PSA are 
bacterial preparations derived from Streptococcus 
pyogenes. 
1）OK-PSA as a specific ligand of TLR4/MD-2 
complex
　We first investigated the role of TLRs in the anti-
cancer host response induced by OK-PSA, an active 
component of OK-432.  Splenocytes from wild type, 
TLR2 －/－ or TLR4 －/－ mice were cultured in the presence 
of OK-PSA or OK-432 for 48h, and the supernatants 
were analyzed for IFN- γ .  Although OK-PSA induced 
IFN- γ on the splenocytes derived from wild type and 
from TLR2 －/－ mice, it did not induce IFN- γ on the 
splenocytes derived from TLR4 －/－ mice.  Unexpectedly, 
OK-432 induced IFN- γ on the splenocytes from all of 
the types of mice examined（Fig. 4A） .  The role of TLR4 
in the in vivo anti-cancer effect of OK-PSA was 
examined.  OK-PSA significantly inhibited the tumor 
growth in wild type-mice, while the anti-cancer effect of 
OK-PSA was not observed in TLR4-mutant mice
（C3H/HeJ）or TLR4 －/－ mice5，20.  Furthermore, we have 
also observed evidence that TLR4 is involved in the DC 
maturation induced by OK-PSA in mice as well as in 
patients with oral cancer11.
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2）Involvement of TLR4 signaling in OK-432-
induced anti-cancer immunity
　The above findings indicate that OK-PSA is a ligand 
of TLR4/MD-2, and that TLR4 signaling is intimately 
involved in OK-PSA-induced anti-cancer immunity, 
whereas the role of TLR4 signaling in the OK-432 effect 
remains uncertain.  We next examined the involvement 
of TLR4 in the anti-cancer effect of OK-432.
2-1）Basic study using TLR4 －/－ mice
　The effect of an in vitro long-term OK-432 treatment 
on changes in IFN- γ production from mouse spleno-
cytes was tested.  At 48-168h after OK-432 stimulation, 
the amounts of IFN- γ secreted by the OK-432-
stimulated splenocytes derived from the TLR4 －/－ mice 
was significantly lower than those from the wild-type 
mice（Fig. 4B） . In the in vivo model, the OK-432 
administration into the mice significantly increased the 
serum IFN- γ levels in the wild-type and TLR2 －/－ mice, 
but not in the TLR4 －/－ mice（Fig. 4C） .  Furthermore, in 
syngeneic-tumor bearing mice, the peritumoral injec-
tion of OK-432 resulted in a marked inhibition of tumor 
growth in the wild-type mice, while in the TLR4 －/－ 
mice, anti-tumor effect of OK-432 was not observed（Fig. 
4） 5.
2-2）Clinical study in oral cancer patients
　We examined whether the expression of TLR4 and 
MD-2 genes may be associated with OK-432-induced 
anti-cancer immunity. PBMCs from 28 patients with 
oral cancer were analyzed for TLR4 and MD-2 mRNA 
expression by reverse transcription-polymerase chain 
reaction（RT-PCR）analysis.  The patients’ sera were 
collected 24h after OK-432 administration either 
peritumorally or intradermally, and were then were 
examined for IFN- γ protein by ELISA.  The results 
are shown in Table 2.  A statistically significant 
relationship between the expression of the TLR4 and 
MD-2 genes and the OK-432-induced IFN- γ production 
was observed（p＝ 0.0005 in Fisher’s exact test） 5. 
　All 28 patients examined in the current study 
received therapy with OK-432 and UFT, an oral 
fluoropyrimidine formulation combining tegafur and 
uracil in a 1:4 ratio（Taiho Pharmaceutical Co., Tokyo, 
Japan） , in combination with radiotherapy. Among these 
patients, 10 of 20 TLR4（＋）MD-2（＋）patients（50％）
became histopathologically tumor-free after the ther-
apy, and without surgical resection.  By contrast, 
all 8 patients who were TLR4（－）or MD-2（－） , 
have surgically resected their tumors, because the 
tumors still remained after the therapy was completed
（Table 2） 5. 
3）Mechanism of OK-432 effect via TLR4 : Role of 
phagocytes
　The findings described above indicate that OK-PSA 
augments anti-cancer immunity via TLR4 signaling, 
that the in vitro IFN- γ -inducing effect of OK-432 not 
via TLR4 is a passing phenomenon, and that TLR4 is 
greatly involved in the in vitro continuous production of 
IFN- γ , and in the in vivo anti-cancer effect induced by 
OK-432.  We previously reported that OK-432 injected 
into tumor-bearing mice is first captured by phago-
cytes48, such as macrophages and DCs.  Thus, we 
hypothesized that OK-PSA, an active component of 
OK-432, which is captured, digested, and released 
by phagocytes, may elicit its effect through TLR4 
signaling, and the in vitro experiments were conducted 
to investigate this working hypothesis.
　We first tested the effect of cytochalasin B（Signa） , a 
phagocytosis inhibitor, in OK-432-induced cytokine 
production.  The blocking of the phagocytosis by 
cytochalasin B significantly inhibited the production 
of cytokines（IFN- γ and IL-12）by mouse peritoneal 
macrophages and human monocyte - derived DCs. 
Similar findings were recently reported by other 
investigators14.  The immunofluorescence staining 
which was performed by using TS-2 mAb recognizing 
OK-PSA revealed that OK-432 was captured and 
digested by macrophages and DCs in vitro（Fig. 5A） . 
OK-PSA was detected in the supernatants from OK-432-
treated DC culture by the ELISA system using TS-2 
mAb as a primary Ab.  In addition, the supernatants 
derived from OK-432-treated DCs increased NF- κ B 
activity in the TLR4/MD-2-expressing cells by a 
luciferase assay system using an NF- κ B-dependent 
reporter construct, and the increased NF- κ B activity 
was significantly neutralized by TS-2 mAb, as well as 
by anti-TLR4 mAb（Fig. 5B）（manuscript in prepara-
tion） .  Stimulation of the TLR4/MD-2-expressing cells 
with OK-432 did not increase the NF- κ B activity5.  The 
mechanism presumed from the results of this study is 
presented in Fig. 5C.
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4. TLR4 ligand, OK-432/OK-PSA, as an adjuvant 
for DC therapy for cancer
　Since their original identification by Steinman, much 
attention has been focused on the role of DCs in 
eliciting the anti -tumor effect and in potential 
therapeutic applications, and recent insights may 
8 Oral Science International　Vol. 1, No. 1
Fig. 4　Involvement of TLR4 in OK-432/OK-PSA-induced anti-cancer immunity.（A）
IFN- γ production by OK-432/OK-PSA-stimulated mice spleen cells. Spleen 
cells（2 × 106/ml）derived from wild type, TLR2 －/－ or TLR4 －/－ mice were 
stimulated with 1 or 10μ g/ml of OK-432 or OK-PSA for 48 h, then IFN- γ in 
the supernatants was analyzed by ELISA. Data represent mean value of 
triplicate samples with upper 95％ confidence intervals（CI）. ＊ , p ＜ 0.01 as 
compared with untreated controls.（B）Effect of extended OK-432 treatment 
on IFN- γ production by mice spleen cells. Spleen cells derived from wild 
type or TLR4 －/－ mice were treated with 0.1 μ g/ml of OK-432 for 0-168 h. 
IFN- γ in the supernatants was measured. Data represent mean value of 
triplicate samples with upper 95％ CI. ＊ , p ＜ 0.01 ; #, p ＜ 0.05 as compared 
with wild-type mice.（C）Wild type, TLR2 －/－ or TLR4 －/－ mice received an 
intraperitoneal injection of OK-432（100μ g） . After 6 days, mice received a 
second intraperitoneal injection of OK-432（100μ g）or physiologic saline. Six 
hours after the second treatment, IFN- γ levels in the sera were measured 
by ELISA. Data represent mean value of triplicate samples with upper 95％ 
CI. ＊ , p ＜ 0.01 as compared with controls given saline.（D）Impairment of 
anti-cancer effect of OK-432 in TLR4 －/－ mice with Lewis lung carcinomas 
LL/2. LL/2-bearing wild type and TLR4 －/－ mice received peritumoral OK-
432 injections twice a week. The tumor volumes were measured. Data 
represent mean value of 8 samples with upper 95％ CI. ＊ , p ＜ 0.01 as 
compared with controls given saline. 
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Table 2　Relationship between expression of TLR4/MD-2 genes and IFN- γ induction by OK-432 administration in oral 
cancer patients. aExpression of TLR4 and MD-2 mRNAs in patient-derived PBMCs were analyzed by 
semiquantitative RT-PCR analysis. Densitometric analysis for the RT-PCR band patterns was done by using NIH 
Image 1.59 software. The relative density（RD）of each specific RT-PCR band was expressed as a ratio to the density 
of GAPDH and RD ＜ 0.1 was defined as － , 0.1 ≦ RD ＜ 0.5 as ± , and RD≧ 0.5 as +. bIFN- γ levels in sera collected 
from the patients 5h before and 24h after OK-432 administration were measured. Serum IFN- γ protein was not 
detectable（i.e., was less than 7.8 pg/ml）in any of the patients before OK-432 treatment（data not shown） . 
Therefore, the cases in that IFN- γ was detected in the sera collected after OK-432 administration, were expressed
“＋” . CAll 28 patients received therapy with OK-432 and UFT in combination with radiotherapy.“＋”means that 
the tumors have surgically resected, because the tumors still remained after the therapy was completed. The 
patients who became histopathologically tumor-free after the therapy, without surgical resection, expressed“－” .
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Fig. 5　Mechanism of OK-432-induced host response : 
phagocytosis, digestion, release of the active 
components, and TLR4 signaling.（A）Oneμ g/ml 
of OK-432 was added into the culture of human 
monocyte-derived DCs or mice peritoneal 
macrophages. After the cultivation for 6, 12, 24 or 
48 h, 100 μ g of the culture media including the 
cells were collected, dropped on glass plates, 
dried, and fixed with 3 ％ paraformaldehyde. 
Immunofluorescence staining using biotinylated 
TS-2 mAb, an anti-OK-PSA mouse IgM, was 
done, then microscopic analysis was conducted 
under the conditions of fluorescent light.（B）
Luciferase assay by using an NF- κ B reporter 
construct was performed. Mouse pro-B cell line 
Ba/F3 stably expressing human TLR4 and MD-2, 
which have been also transfected with p55Ig κ
 Luc, an NF- κ B reporter construct, were treated 
with LPS（100 ng/ml）, OK-PSA（1 μ g/ml）or 
the filtrated supernatants derived from OK-432-
treated DC culture（OK-432 DC Sup.） . After 5 h-
treatment, cells were harvested and lysed, and 
luciferase activity was measured. Bars denote SD 
of triplicate samples. ＊ , p ＜ 0.01 as compared with 
controls pretreated with control Ab.（C）Schema 
of the mechanism of OK-432-induced host 
response.
provide the basis for generating more effective anti-
tumor immune responses49，50.  In most tissues, 
including tumor tissues, DCs are present in an 
immature state.  The immature DCs（iDCs）are unable 
to stimulate T cells, and are extremely well equipped to 
capture antigens. In the primary tumor sites, the 
antigen-bearing iDCs that are followed by appropriate 
maturation, and that strongly express CD80, CD83, 
CD86, MHC class I and MHC class II, migrate to the 
paracortical T cell-rich area of the draining lymph 
nodes, present antigens to T cells, and induce tumor-
specific CTLs as well as helper T lymphocytes50.  The 
immunomodulator that can induce the maturation of 
human DCs, e.g., TLR ligands, may be a useful 
adjuvant for DC-based immunotherapy in patients with 
malignant diseases. In this section, we demonstrate the 
effect of OK-432/OK-PSA, which can mature DCs in 
vitro as described above, as an adjuvant for local DC 
therapy.
　We conducted a mouse model to examine the in vivo 
anti-cancer effect of an intratumoral administration of 
iDCs in combination with OK-432.  Apoptotic tumor 
cells are relatively easy to be captured and processed, 
and present their antigens to T cells by DCs present 
in tumor tissues.  Thus, we used TS-1, an oral 
fluoropyrimidine anti-cancer drug combining tegafur, 
Gimeracil, and Oteracil Calcium in a 1 : 0.4 : 1 ratio
（Taiho） , to induce the apoptosis of cancer cells before an 
injection of iDCs and OK-432.  We have already 
reported that a relatively low dose of 5-fluorouracil（5-
FU）causes the augmentation rather than the inhibition 
of anti-cancer immunity mediated by the induction of 
cytokines and killer cell activities in patients with oral 
cancer51，52.  In syngeneic tumor-bearing BALB/c mice, 
after the apoptosis of tumor cells was induced by 1-
week oral administration of TS-1, syngeneic bone-
marrow-derived iDCs were injected intratumorally, and 
then the intratumoral administration of OK-432 was 
done at 6h after the DC injection to induce their 
maturation.  This local DC therapy in combination with 
TS-1 and OK-432 significantly regressed the growth of 
tumors in both the injection and distant sites.  However, 
tumors grew rapidly in the control and iDC+OK-432 
groups.  TS-1 alone initially suppressed tumor growth, 
but could not sustain this suppression, and a significant 
difference was observed from that of the TS-1 ＋ DC ＋
OK-432 group in the degree of suppression of tumor 
growth（Fig. 6A） .  Consistent with the significant 
regression of tumor growth in the mice treated with TS-
1 ＋ DC ＋ OK-432, the same group also showed the 
highest survival rate（Fig. 6B） .  Tumor infiltrating 
lymphocytes and draining lymph node cells derived 
from the mice in the TS-1 ＋ DC ＋ OK-432-treated group, 
but not in the other groups, elicited a marked cytotoxic 
activity against the inoculated tumor cells, but not 
against the non-specific target cells, and the major 
effector cells of the cytotoxicity were MHC class 1-
restricted CD8 ＋  T cells. Furthermore, we also observed 
that the therapy was not effective in TLR4-deficient 
mice bearing syngeneic tumors53.
　An early-stage clinical trial of local DC therapy 
against oral cancer, in combination with chemothera-
peutic agents and OK-432, is currently taking place, 
and the preliminary findings from these trials are 
encouraging.
Discussion and future perspectives
　Although the major therapies for patients with oral 
cancers are surgical resection, radiotherapy, and 
chemotherapy, the accumulated evidence demonstrates 
that stimulating the anti-cancer host response is 
essential to completely eliminating the remaining 
cancer cells, e.g., the micro-invaded or micro-metastatic 
cancer cells, and the radio- and/or chemo-resistant 
cancer cells.  In addition, the induction of memory T 
lymphocytes, which recognize tumor antigen （s） , is an 
important component in preventing the recurrence of 
tumors.  Augmenting anti-cancer immunity in patients 
is important both for curing the diseases, and for 
increasing the quality of life of cancer patients.
　Recent studies strongly suggest that TLR ligands can 
be usefully applied for immunotherapy for cancer 
patients.  The schema of TLR ligand-induced anti-
cancer immunity is shown in Fig. 7.  In cancer tissues, 
DCs bearing tumor antigen （s）may be stimulated by 
bacterial components such as OK-432/OK-PSA, BCG-
CWS, or CpG-DNA via TLRs.  TLR-mediated signaling 
stimulates the maturation of DCs.  The matured DCs, 
in which the expression of MHC and costimulatory 
molecules has been increased by TLR stimulation, 
migrate to the regional lymph nodes, and then present 
antigen （s）to the T cells.  TLR-stimulated DCs also 
enhance the producing ability of cytokines such as IL-12 
and IL-18, which are potential Th1-inducing cytokines. 
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Fig. 7　Schema of the mechanism for establishment of anti-cancer immunity induced by TLR ligands.
Fig. 6　Anti-tumor effect of an intratumoral administration of DCs in combination 
with TS-1 and OK-432. BALB/c mice were inoculated s.c. with syngeneic 
fibrosarcoma cells Meth-A（1× 105/mouse）in both right and left flanks. Four 
days after tumor inoculation, some groups of mice received oral dose（200μ g/
 mouse/day）of TS-1 and continued for 7 days. On day 12, some groups of mice 
received intratumoral DC injection（2 × 106 /mouse）and the same mouse 
received intratumorally OK-432（1 KE : 100μ g/mouse）6 h after DC therapy.
（A）Tumor volume. Bars denote SD of 8 determinants. ＊ . p ＜ 0.01 ; #, p ＜ 0.05 
as comoared with control given saline.（B）Survival rate. ＊ . p ＜ 0.01 ; #, p ＜ 0.05 
as comoared with control given saline. N ＝ 8. 
Therefore, TLR-stimulated DCs may effectively induce 
tumor-antigen specific Th1 and CTL by presenting 
antigens to the CD4 ＋ and CD8 ＋ T cells while promoting 
a Th1-leading situation.  In addition, some TLR ligands 
activate NK cells which express several types of TLRs, 
including TLR2, TLR4, and TLR954，55.  Then, the 
activated NK cells elicit non-specific killing against 
cancer cells, as well as induce IFN- γ .  It is possible that 
certain ligands of TLRs are able to be effective 
immunotherapeutic agents for patients with cancer.
　Because of the discovery of TLRs as immunoadjuvant 
receptors, great progress has been made in the use 
of immunoadjuvants to treat human cancer.  The 
expression of TLRs in patients may prove a useful 
marker to discriminate between responders and non-
responders to TLR ligands used therapeutically.  Strong 
support is provided for this opinion by the clinical study 
we conducted in oral cancer patients,which is described 
in section 3. 2-2）, and in Table 25.  For example, if a 
patient does not express TLR4/MD-2, BCG-CWS or 
CpG-DNA but not OK-432/OK-PSA should be selected 
as a therapeutic application.  In addition, the transfer 
of the genes encoding TLR4/MD-2 may be effective to 
augment the anti-cancer effect of OK-432/OK-PSA 
in these patients.  This possibility is now under 
investigation in our laboratory.
　The residual problem is that all types of signaling 
mediated by TLRs do not induce the Th1-type T-cell 
response.  Although Agrawal et al. recently demon-
strated that signaling via TLR4 and TLR5 but not via 
TLR2 stimulates the Th1-type host response56, the 
molecular mechanism for this difference between TLR4, 
TLR5, and TLR2 remains uncertain.  The downstream 
molecular events of TLRs which induce the Th1 
response need to be clarified, because the establishment 
of a Th1-dominant state in cancer patients is of great 
importance in curing malignant diseases.
　The findings of our studies strongly suggest that 
TLR4 signaling is involved in regulating anti-cancer 
immunity induced by OK-PSA which is an LTA- 
related molecule. Several investigators reported that 
Gram-positive bacteria-derived LTA is recognized by 
TLR457，58, whereas it has been also reported that TLR2 
recognizes LTA59, as shown in Table 1.  Recent studies 
by Hartung et al. have demonstrated that the butanol-
extracted LTA in addition to synthetic LTA from 
Staphylococcus aureus induce cytokines through TLR2 
but not through TLR460，61.  Further, it was also reported 
that LTA from Bacillus subtilis and from Staphylococ-
cus aureus induced the maturation of murine DCs via 
TLR262.  Since TS-2 mAb recognizes LTAs15, and 
neutralizes LTA-induced cytokine production63, it is 
suggested that OK-PSA has a certain chemical 
structure that LTAs share in common, whereas OK-PSA 
is not always consistent with several known molecules 
in LTA family in cytokine-inducing activity and in 
chemical and physical characteristics as described in 
the section “Isolation of OK-PSA”.  In addition, recent 
evidence in LPS recognition suggests that there are 
structural and functional differences among LPS 
molecules from different bacteria.  An LPS with a 
conical shape（e.g. from Escherichia coli）induces 
cytokines via TLR4, while a more cylindrical LPS（e.g. 
from Porphyromonas gingivalis）induces a different set 
of cytokines via TLR264. It is possible that OK-PSA, a 
ligand for TLR4, may be a novel member of the LTA 
family with a different structure.  Our laboratories are 
currently working to determine the chemical structure 
of OK-PSA.
　The original OK-432, a whole bacterial preparation, 
contains many components which may induce Th2-type 
cytokines and cause serious side effects1，30.  Further-
more, although OK-432 should be captured and 
digested by phagocytes before eliciting its anti-cancer 
effect, OK-PSA directly activates TLR4 signaling.  We 
believe that OK-PSA, which augments the anti-cancer 
immune response by acting as a potent Th1 inducer far 
better than the original OK-432, could possibly be 
applied clinically in therapies used for treating human 
cancers, including oral cancer.  Before attempting to 
apply these agents to the treatment of human cancers, 
the chemical structure of OK-PSA needs to be fully 
determined.  It is now under investigation in our 
laboratories as described above, and we expect to be 
able to conduct clinical trials in the future.
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